Alembic Pharmaceuticals Statistics

Total Valuation

BOM:533573 has a market cap or net worth of INR 176.07 billion. The enterprise value is 187.73 billion.

Market Cap	176.07B
Enterprise Value	187.73B

Important Dates

The last earnings date was Thursday, May 8, 2025.

Earnings Date	May 8, 2025
Ex-Dividend Date	Jul 15, 2024

Share Statistics

Current Share Class	196.56M
Shares Outstanding	n/a
Shares Change (YoY)	+0.00%
Shares Change (QoQ)	-0.43%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	57.35M

Valuation Ratios

The trailing PE ratio is 30.18 and the forward PE ratio is 24.61.

PE Ratio	30.18
Forward PE	24.61
PS Ratio	2.64
PB Ratio	3.39
P/TBV Ratio	3.39
P/FCF Ratio	n/a
P/OCF Ratio	200.15
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.60, with an EV/FCF ratio of -39.47.

EV / Earnings	32.18
EV / Sales	2.81
EV / EBITDA	18.60
EV / EBIT	25.70
EV / FCF	-39.47

Financial Position

The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.24.

Current Ratio	1.69
Quick Ratio	0.62
Debt / Equity	0.24
Debt / EBITDA	1.25
Debt / FCF	-2.64
Interest Coverage	9.26

Financial Efficiency

Return on equity (ROE) is 11.63% and return on invested capital (ROIC) is 7.74%.

Return on Equity (ROE)	11.63%
Return on Assets (ROA)	6.41%
Return on Invested Capital (ROIC)	7.74%
Return on Capital Employed (ROCE)	13.61%
Revenue Per Employee	4.49M
Profits Per Employee	392,664
Employee Count	14,858
Asset Turnover	0.94
Inventory Turnover	0.91

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -7.49% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-7.49%
50-Day Moving Average	856.31
200-Day Moving Average	1,022.12
Relative Strength Index (RSI)	50.59
Average Volume (20 Days)	6,512

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, BOM:533573 had revenue of INR 66.72 billion and earned 5.83 billion in profits. Earnings per share was 29.68.

Revenue	66.72B
Gross Profit	48.79B
Operating Income	7.30B
Pretax Income	7.07B
Net Income	5.83B
EBITDA	10.08B
EBIT	7.30B
Earnings Per Share (EPS)	29.68

Full Income Statement

Balance Sheet

The company has 901.00 million in cash and 12.58 billion in debt, giving a net cash position of -11.67 billion.

Cash & Cash Equivalents	901.00M
Total Debt	12.58B
Net Cash	-11.67B
Net Cash Per Share	n/a
Equity (Book Value)	51.90B
Book Value Per Share	264.03
Working Capital	16.75B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 879.70 million and capital expenditures -5.64 billion, giving a free cash flow of -4.76 billion.

Operating Cash Flow	879.70M
Capital Expenditures	-5.64B
Free Cash Flow	-4.76B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 73.12%, with operating and profit margins of 10.94% and 8.74%.

Gross Margin	73.12%
Operating Margin	10.94%
Pretax Margin	10.60%
Profit Margin	8.74%
EBITDA Margin	15.11%
EBIT Margin	10.94%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 11.00, which amounts to a dividend yield of 1.24%.

Dividend Per Share	11.00
Dividend Yield	1.24%
Dividend Growth (YoY)	37.50%
Years of Dividend Growth	1
Payout Ratio	37.06%
Buyback Yield	-0.00%
Shareholder Yield	1.24%
Earnings Yield	3.31%
FCF Yield	-2.70%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a